Molecular Quality Controls Market Size is set to expand significantly over 2022-2028, as a result of the rise in prevalence of cancers, HIV, and other diseases that required robust diagnostic methods for effective treatment. Molecular quality control refers to the testing and reporting of any irregularity in diagnostic products, which can affect decisions regarding approval of the product for use in laboratories. Molecular laboratories use thorough QC (quality control) procedures to supervise the testing for both systematic as well as random errors and detect immediate shifts in data and abnormalities in long-term trends. Early detection of potential anomalies is crucial for laboratories, as it helps them implement a timely response and avoid negative impacts on patient data.
Global molecular quality controls market trends are powered by various factors, such as the persistent rise in the number of accredited clinical laboratories. In September 2021, for instance, CAP (College of American Pathologists) awarded accreditation to UC Berkeley’s Innovative Genomics Institute Clinical Laboratory, on the basis of results from an on-site inspection conducted as part of the CAP’s Accreditation Programs. This rise in clinical facilities will create an urgent demand for thorough monitoring and testing for potential irregularities in diagnostic products, which could, in turn, augment demand for molecular quality control solutions over the years ahead.
With regards to application, the molecular quality controls market from the oncology segment is expected to gain rapid traction by 2028. Proliferating research efforts on cancer and associated biomarkers is a major driver behind this growth. For example, research presented at an annual meeting of the European Society of Medical Oncology estimates that cancer incidence will increase by almost 21% between 2020 and 2040. Furthermore, efforts related to biomarker discovery are also growing rapidly, such as Roche’s introduction of the AVENIO Tumor Tissue CGP Kit in October 2021, designed to help labs expand in-house oncology research.
Asia Pacific molecular quality controls market will register substantial growth through 2028, owing to the rise in demand for accurate and high-quality diagnostics tests. With cancer becoming an increasingly prevalent health issue in the APAC region, owing to aging populations and changes in lifestyle, the need for precision oncology has been a major area of focus of various authorities in the region, triggering the establishment of various initiatives. These include the establishment of platforms such as the K-MASTER (Korean Cancer Precision Medicine Diagnosis and Treatment Enterprise) in South Korea, as well as Japan’s LC-SCRUM lung cancer genomic screening project.
ZeptoMetrix Corporation (Antylia Scientific), Bio-Rad Laboratories Inc., Microbiologics Inc, Qnostics Ltd (Alere Inc., BBI HOLDINGS PLC), SeraCare Life Sciences Inc. (LGC Standards Ltd.), Quidel Corporation, Abbott Laboratories, Maine Molecular Quality Controls Inc., Roche Diagnostics, and Thermo Fisher Scientific are among the major contenders contributing to molecular quality controls industry share. These players are undertaking various strategic initiatives, such as partnerships and collaborations to establish a stronghold in the global molecular quality controls market. For instance, in December 2020, Bio-Rad Laboratories, Inc. and Siemens Healthineers announced the expansion of their joint marketing agreement. Under the terms of the deal, Bio-Rad would deliver quality control solutions and its Unity Quality Control data management solutions for the Atellica Solution platforms of Siemens Healthineers.
The onset of the novel coronavirus outbreak has created unprecedented disruptions across the globe. While this disruptive force has created upheavals for many industrial sectors, the molecular quality controls market could flourish significantly during the pandemic, as clinical laboratories and diagnostic manufacturers make efforts to address the growing demand for testing solutions, which are considered essential aspects of COVID-19 disease management. To that end, ZeptoMetrix announced the addition of another important molecular quality control to its vast Infectious Disease NATtrol™ Quality Controls line. Dubbed the SARS-CoV-2 Variant Panel, the solution includes four individual, separate vials of each of the variants, Alpha, Beta, Gamma, and Delta. Developments such as these could contribute to the growing demand for molecular quality control solutions over the foreseeable future.
Market, by Product type
Market, by Analyte type
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: